Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Schering Jumps On Organon Buy; Will Late-Stage M&A Keep Fueling Pharma?

Executive Summary

Pharmaceutical companies unveiling mergers and acquisitions in the first quarter were among those rewarded by Wall Street

You may also be interested in...

Will Schering-Plough’s Vytorin Headache Prove Contagious?

The full impact of Schering-Plough's deepening woes after a scientific panel's negative analysis of the Vytorin ENHANCE trial will not be known for a while, and some analysts predict there could be repercussions beyond the company and its joint venture with Merck, a deal centered on the anti-cholesterol drug, which combines the statin Zocor (simvastatin) withZetia (ezetimibe)

Schering Sees Growth Opportunity For Organon Products In The U.S. – Hassan

Schering-Plough sees significant growth potential for Organon's products that currently are marketed in the U.S., CEO Fred Hassan said March 20

Sanofi Tries To Quash Bristol Rumors; M&A Efforts Center On Biotech, Japan

Sanofi-Aventis' merger and acquisition efforts will focus on biotech firms and Japanese companies, CEO Gerard Le Fur maintained Feb. 13

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts